We use cookies for a better user experience. Read our Privacy Policy

I Agree

Ischemia Reperfusion Injury Therapeutics Market

Ischemia Reperfusion Injury Therapeutics Market (Treatment: Drug Therapy, Medicated Gases, and Others: Injury Type: Heart Injury, Kidney Injury, Intestine Injury, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Ischemia Reperfusion Injury Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 2.3 Bn in 2021
  • It is projected to grow at a CAGR of 3.5% from 2022 to 2031 and reach more than US$ 3.2 Bn by the end of 2031

Analysts’ Viewpoint

The global ischemia reperfusion injury therapeutics market is driven by rise in prevalence of cardiovascular diseases, increase in geriatric population, and surge in awareness about ischemia reperfusion injuries among healthcare professionals and patients. Advancements in technology and development of new and effective therapies present significant opportunities for manufacturers in the market. Furthermore, government initiatives and funding for research & development of new therapies support market development.

The COVID-19 pandemic led to a decrease in the number of elective surgeries, leading to a decline in number of cases of ischemia reperfusion injury. Additionally, the pandemic led to a decrease in funding for research & development. However, surge in focus on COVID-19 treatments contributed to new discoveries and advancements that could benefit the treatment of ischemia reperfusion injury in future.

Ischemia Reperfusion Injury Therapeutics Market

Ischemia Reperfusion Injury Therapeutics Market Introduction

Ischemia-reperfusion injury (IRI) occurs when blood flow to an area of tissue is blocked (ischemia) and subsequently restored (reperfusion). This could happen during situations, such as heart attack, stroke, or surgery, where a blood vessel is temporarily blocked and then reopened. During ischemia, the tissue is deprived of oxygen and nutrients, which could cause damage to cells and tissues. When blood flow is restored (reperfusion), the sudden influx of oxygen can cause a cascade of harmful reactions, including inflammation and the generation of reactive oxygen species (ROS), leading to further damage to the tissue. This injury could lead to functional and structural impairments of the organ, such as myocardial infarction, stroke, and kidney injury.

A rise in a number of patients requiring treatment for IRI due to an increase in the incidence of cardiovascular diseases and organ transplants is driving market expansion. The surge in healthcare expenditure and rise in awareness about IRI and its treatment options are propelling market progress.

Development of new drugs and therapies that can effectively target and treat IRI and expansion of existing treatments into new indications are augmenting the market. Increase in incidence of IRI-related conditions, such as heart attack and stroke, is expected to bolster global ischemia reperfusion injury therapeutics market growth. Development of new diagnostic tools and increase in usage of telemedicine and other digital technologies to improve patient outcomes present significant opportunities for companies in the industry.

Rise in Prevalence of Cardiovascular Diseases

Increase in patient population in need of IRI treatment due to rise in prevalence of cardiovascular diseases, such as heart attack and stroke, is driving ischemia-reperfusion injury therapeutics market share. The ischemia-reperfusion injury could occur during certain medical procedures, such as angioplasty, and is a leading cause of tissue damage in patients with cardiovascular disease. Ischemia-reperfusion injury therapeutics market demand is expected to be driven by aging population and increase in risk factors for cardiovascular diseases, such as obesity and diabetes.

Cardiovascular diseases (CVDs) is a leading cause of death across the world. According to the World Health Organization (WHO), CVDs are a major cause of death globally, accounting for 17.9 million deaths per year. Prevalence of CVDs is increasing due to aging population and surge in risk factors such as obesity and diabetes. Additionally, CVDs are more common in low- and middle-income countries, where access to healthcare and preventative measures is limited.

Increase in Awareness about Diseases among Healthcare Professionals and Patients

Surge in awareness about IRI among healthcare professionals and patients is driving the demand for effective treatments. Awareness among healthcare professionals about this condition is rising due to education and training. This, in turn, is likely to increase diagnosis and treatment. Patients are more informed about the condition and its potential complications. Surge in awareness about IRI is leading to rise in research & development and introduction of a number of products to treat the condition.

Awareness about IRI is rising due to increase in research and understanding of the mechanisms involved and the potential interventions that could be used to mitigate its effects. Additionally, usage of ischemia reperfusion in various clinical settings, such as organ transplantation and cardiopulmonary bypass surgery, has led to increase in attention and awareness about the condition. Furthermore, growing interest in regenerative medicine has led to increase in focus on the role of ischemia reperfusion in tissue injury and repair. Therefore, rise in awareness among healthcare professionals and patients is projected to drive the demand for ischemia reperfusion injury therapeutics during the forecast period.

Development of New and Effective Therapies

Development of new and effective therapies for IRI that are more effective and have fewer side effects than current therapies is expected to bolster ischemia reperfusion injury therapeutics market growth. This is likely to lead to increase in demand for these therapies and rise in revenue of companies. Additionally, ongoing research and development in IRI therapeutics could lead to discovery of new targets and mechanisms for therapy. This, in turn, is projected to accelerate market growth.

Development of new and effective therapies, such as drugs that can target specific pathways or molecules involved in the injury process, in anticipated to propel the industry. For instance, drugs that inhibit inflammation or oxidative stress could help reduce tissue damage caused by IRI.

Usage of regenerative medicine techniques, such as stem cell therapy, to repair or replace damaged cells and tissues could lead to the development of therapies that can help restore function to the affected area and reduce the risk of complications. Additionally, new technologies, such as remote monitoring and telemedicine, are being used to improve the diagnosis and treatment of IRI.

Recent developments in new therapies for IRI include usage of stem cells and exosomes, pharmacological agents such as statins and phosphodiesterase inhibitors, and utilization of remote ischemic preconditioning. Other promising areas of research are usage of hyperbaric oxygen therapy and utilization of extracorporeal devices to remove damaging molecules from the blood.

Widely Accepted Treatment Option

In terms of treatment, the drug therapy segment dominated the global ischemia reperfusion injury therapeutics market in 2021. Drugs are widely accepted and established form of treatment for IRIs. These drugs, which target inflammation or oxidative stress, could effectively reduce the damage caused by IRIs and improve patient outcomes. Additionally, development of new and more effective drugs for treating IRI is ongoing. This is expected to drive the drug therapy segment in the next few years.

Rise in Heart Attacks Globally

Based on injury type, the heart injury segment accounted for the largest share of the global market in 2021. Heart injury is a common type of IRI. Heart attack is a leading cause of death and disability across the world. Furthermore, advances in medical technology, such as development of new drugs and procedures for treating heart attacks, is projected to augment the heart injury segment.

Regional Outlook of Global Ischemia Reperfusion Injury Therapeutics Market

North America dominated the global ischemia reperfusion injury therapeutics industry in 2021. Incidence of IRI is high in the region due to significant prevalence of cardiovascular diseases and large number of surgeries performed. Additionally, well-established healthcare infrastructure enables early diagnosis and treatment of IRI in North America. Governments in the region support the development and promotion of new treatments for IRI through funding and incentives for research & development. High healthcare expenditure also contributes to the growth of the market in North America, as patients have access to advanced treatments and technologies.

The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. This is ascribed to increase in geriatric population, which is more susceptible to IRI, and rise in awareness among healthcare professionals and general public. Expanding healthcare infrastructure and increase in availability of advanced medical technologies contribute to market growth in the region. Furthermore, rise in number of surgical procedures and increase in focus on organ transplantation drive the market in Asia Pacific.

Analysis of Key Players

This report provides profiles of leading players operating in the global ischemia reperfusion injury therapeutics market. These include Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., SBI Pharmaceuticals, Faraday Pharmaceuticals, and Zealand Pharma A/S. These players engage in merger & acquisition, strategic collaborations, and new product launches to expand market presence.

Key Developments in Global Ischemia Reperfusion Injury Therapeutics Market

  • In March 2022, SBI Pharmaceuticals and the University of Oxford announced that the former initiated a phase II clinical trial to develop a cardioprotective agent combining 5-ALA hydrochloride and sodium ferrous citrate for the mitigation of IRI in response to cardiac surgery under cardiopulmonary bypass. The trial is sponsored by both parties under the clinical trial sponsorship agreement.
  • In November 2019, Faraday Pharmaceuticals announced progressive results from the phase II clinical trials of FDY-5301. It is a sodium iodide containing, formulated, patented, elemental reducing agent. It works by destroying hydrogen peroxide, which is naturally produced as a response to acute ischemia reperfusion injury and contributes to muscle function and mass loss. The drug is being developed to treat ischemia reperfusion injury caused by a STEMI heart attack.

Leading players have been profiled in the report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Ischemia Reperfusion Injury Therapeutics Market Snapshot

Attribute

Detail

Size in 2021

US$ 2.3 Bn

Forecast (Value) in 2031

More than US$ 3.2 Bn

Growth Rate (CAGR) 2022-2031

3.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Treatment
    • Drug Therapy
    • Medicated Gases
    • Others
  • Injury Type
    • Heart Injury
    • Kidney Injury
    • Intestine Injury
    • Others
  • End-user
    • Hospitals
    • Specialty Clinics
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amyndas Pharmaceuticals LLC
  • Angion
  • Bolder Biotechnology
  • Opsona Therapeutics Ltd.
  • Pharming Group NV
  • Prolong Pharmaceuticals
  • Prothix BV
  • Stealth BioTherapeutics, Inc.
  • Zealand Pharma A/S
  • Faraday Pharmaceuticals
  • SBI Pharmaceuticals

Customization Scope

Available upon request

Pricing

Available upon request

Ischemia Reperfusion Injury Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global ischemia reperfusion injury therapeutics market in 2021?

The global market was valued at US$ 2.3 Bn in 2021

How big will it be in 2031?

It is projected to reach more than US$ 3.2 Bn by 2031

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 3.5% from 2022 to 2031

Which segment held major share?

The drug therapy segment accounted for significant share in 2021

Which region will account for leading share?

North America is expected to account for the largest share during the forecast period.

Who are the prominent players in the market?

Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Faraday Pharmaceuticals, SBI Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., and Zealand Pharma A/S.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ischemia Reperfusion Injury Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Development

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Disease Epidemiology

    5.2. Pipeline Analysis

    5.3. COVID 19 Impact on Industry

6. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Treatment

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment, 2017–2031

        6.3.1. Drug Therapy

        6.3.2. Medicated Gases

        6.3.3. Others

    6.4. Market Attractiveness Analysis, by Treatment

7. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Injury Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Injury Type, 2017–2031

        7.3.1. Heart Injury

        7.3.2. Kidney Injury

        7.3.3. Intestine Injury

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by Injury Type

8. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2017–2031

        8.3.1. Hospitals

        8.3.2. Specialty Clinics

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by End-user

9. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment, 2017–2031

        10.2.1. Drug Therapy

        10.2.2. Medicated Gases

        10.2.3. Others

    10.3. Market Value Forecast, by Injury Type, 2017–2031

        10.3.1. Heart Injury

        10.3.2. Kidney Injury

        10.3.3. Intestine Injury

        10.3.4. Others

    10.4. Market Value Forecast, by End-user, 2017–2031

        10.4.1. Hospitals

        10.4.2. Specialty Clinics

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Treatment

        10.6.2. By Injury Type

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment, 2017–2031

        11.2.1. Drug Therapy

        11.2.2. Medicated Gases

        11.2.3. Others

    11.3. Market Value Forecast, by Injury Type, 2017–2031

        11.3.1. Heart Injury

        11.3.2. Kidney Injury

        11.3.3. Intestine Injury

        11.3.4. Others

    11.4. Market Value Forecast, by End-user, 2017–2031

        11.4.1. Hospitals

        11.4.2. Specialty Clinics

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Treatment

        11.6.2. By Injury Type

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment, 2017–2031

        12.2.1. Drug Therapy

        12.2.2. Medicated Gases

        12.2.3. Others

    12.3. Market Value Forecast, by Injury Type, 2017–2031

        12.3.1. Heart Injury

        12.3.2. Kidney Injury

        12.3.3. Intestine Injury

        12.3.4. Others

    12.4. Market Value Forecast, by End-user, 2017–2031

        12.4.1. Hospitals

        12.4.2. Specialty Clinics

        12.4.3. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Treatment

        12.6.2. By Injury Type

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment, 2017–2031

        13.2.1. Drug Therapy

        13.2.2. Medicated Gases

        13.2.3. Others

    13.3. Market Value Forecast, by Injury Type, 2017–2031

        13.3.1. Heart Injury

        13.3.2. Kidney Injury

        13.3.3. Intestine Injury

        13.3.4. Others

    13.4. Market Value Forecast, by End-user, 2017–2031

        13.4.1. Hospitals

        13.4.2. Specialty Clinics

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Treatment

        13.6.2. By Injury Type

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Treatment, 2017–2031

        14.2.1. Drug Therapy

        14.2.2. Medicated Gases

        14.2.3. Others

    14.3. Market Value Forecast, by Injury Type, 2017–2031

        14.3.1. Heart Injury

        14.3.2. Kidney Injury

        14.3.3. Intestine Injury

        14.3.4. Others

    14.4. Market Value Forecast, by End-user, 2017–2031

        14.4.1. Hospitals

        14.4.2. Specialty Clinics

        14.4.3. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Treatment

        14.6.2. By Injury Type

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. Amyndas Pharmaceuticals LLC

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Product Portfolio

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. Angion

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Product Portfolio

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. Bolder Biotechnology

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Product Portfolio

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Opsona Therapeutics Ltd.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Product Portfolio

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Pharming Group NV

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Product Portfolio

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. Prolong Pharmaceuticals

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Product Portfolio

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. Prothix BV

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Product Portfolio

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Stealth BioTherapeutics, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Product Portfolio

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Zealand Pharma A/S

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Product Portfolio

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

        15.3.10. Faraday Pharmaceuticals

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Product Portfolio

            15.3.10.3. Financial Overview

            15.3.10.4. SWOT Analysis

        15.3.11. SBI Pharmaceuticals

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Product Portfolio

            15.3.11.3. Financial Overview

            15.3.11.4. SWOT Analysis

            15.3.11.5. Strategic Overview

List of Tables

Table 01: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 02: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

Table 03: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 06: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

Table 07: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 08: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 10: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

Table 11: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 14: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

Table 15: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 18: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

Table 19: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 22: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

Table 23: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

List of Figures

Figure 01: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 03: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 04: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

Figure 05: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

Figure 06: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 07: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 08: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Region, 2021 and 2031

Figure 09: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

Figure 10: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 11: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 12: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 13: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

Figure 14: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

Figure 15: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 16: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 17: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country, 2021 and 2031

Figure 18: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 19: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 20: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 21: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 22: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

Figure 23: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

Figure 24: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 25: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 26: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 27: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 28: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 29: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 30: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 31: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

Figure 32: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

Figure 33: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 34: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 35: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 36: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 37: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 38: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 39: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 40: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

Figure 41: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

Figure 42: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 43: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 44: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 45: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 46: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 47: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

Figure 48: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

Figure 49: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

Figure 50: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

Figure 51: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 52: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 53: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 54: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 55: Global Ischemia Reperfusion Injury Therapeutics Market Share Analysis, by Company, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

399

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved